Artificial intelligence (AI) continues to revolutionize various industries, and AI in healthcare is no exception. Investors eager to capitalize on AI-driven innovation have seen many stocks soar, but some promising companies have lagged. Two such stocks—Recursion Pharmaceuticals (NASDAQ: RXRX) and Teladoc Health (NYSE: TDOC)—are struggling despite their ambitious AI-driven strategies. Could they still be worth the investment?
1. Recursion Pharmaceuticals: AI-Powered Drug Discovery
Revolutionizing Drug Development
Recursion Pharmaceuticals aims to expedite the slow and costly drug discovery process using AI. Traditional drug development can take over a decade and cost hundreds of millions, leaving companies with limited time to generate revenue before patents expire. Recursion’s AI-driven platform accelerates this process by testing compounds against a vast library of human genes, potentially reducing development time and costs.
Promising Partnerships and Pipeline
The company collaborates with pharmaceutical giants like Roche and Bayer, securing essential funding. With more than half a dozen programs in clinical studies, Recursion has demonstrated early success in advancing drug candidates faster than industry norms.
Risks and Challenges for AI in Healthcare
Despite its potential, Recursion has yet to bring a single drug to market or reach late-stage clinical trials. The company faces hurdles, including regulatory challenges, competition from other AI-powered drug discovery firms, and uncertainties regarding its platform’s long-term viability. Investors must weigh these risks against the company’s potential upside.
2. Teladoc Health: AI-Driven Telemedicine Innovation
AI in Healthcare
Teladoc Health, a leader in telemedicine, has faced headwinds in recent years, including slowing revenue growth and increased competition. To regain momentum, the company is integrating AI into its services, including:
- Chronic Health Management: AI predicts risks for type 2 diabetes patients and provides personalized recommendations, improving health outcomes.
- Hospital Safety Solutions: AI-powered Virtual Sitter technology detects patient movements to prevent falls.
Growth Potential and Challenges
Despite a 1% revenue decline to $2.6 billion in 2024, Teladoc’s international sales surged 12% to $409 million. With a vast user base exceeding 90 million, the company has significant growth potential. However, high marketing expenses and fierce competition in the telemedicine sector remain concerns.
Read More: Zhipu AI Launches Free AutoGLM Rumination, Challenging China’s AI Market
Should You Invest?
Both Recursion Pharmaceuticals and Teladoc Health present high-risk, high-reward opportunities. Investors willing to navigate volatility may find long-term gains if these companies successfully execute their AI-driven strategies. However, caution is advised as both firms still have significant challenges ahead.